CCM
PCVX icon

CAAS Capital Management’s Vaxcyte PCVX Stock Holding History

CAAS Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$988K – 900
2020
Q3 		$988K Hold
20,000
– – 0.02% 343
2020
Q2 		$632K Buy
+20,000
New +$643K 0.02% 293

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's PCVX Position: Q4 2020 in Review

CAAS Capital Management sold out of Vaxcyte (PCVX) in Q4 2020, closing a stake of 20,000 shares — an estimated $988K sold.

CAAS Capital Management first reported a position in PCVX in Q2 2020 and held it in 2 quarters. The position peaked at $988K in Q3 2020. 83 funds tracked by Wall St. Rank hold PCVX as of Q4 2020.

  • CAAS Capital Management reported no remaining Vaxcyte position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 20,000 Vaxcyte shares in Q4 2020, an estimated $988K.
  • CAAS Capital Management first reported a position in Vaxcyte in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Vaxcyte position peaked at $988K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.